Allogene Highlights Dual-Target CAR-T Approach at AACR
Event summary
- Allogene presented preclinical data at AACR 2026 on dual CAR T cells targeting BCMA and CD70 for high-risk multiple myeloma.
- CEO David Chang presented a symposium, 'Allogeneic CAR-T: Science at Scale,' outlining the company’s approach to allogeneic CAR T therapy.
- Allogene’s R&D Chief Zachary Roberts participated in a forum discussing the evolving landscape of cell therapies.
- The company is extending its Dagger® technology into autoimmune disease, applying its gene-edited, dual-targeting CAR T approach.
The big picture
Allogene’s focus on allogeneic CAR T therapy represents a strategic bet on simplifying cell therapy manufacturing and expanding patient access. While autologous CAR T therapies have demonstrated clinical efficacy, their complexity and cost have limited their reach. Allogene’s approach aims to overcome these limitations, but faces challenges in ensuring robust efficacy and managing potential immune responses against the allogeneic cells. The company's reliance on Cellectis for key technologies also introduces a degree of dependency.
What we're watching
- Clinical Efficacy
- The success of the BCMA/CD70 dual CAR T approach will hinge on demonstrating durable responses and manageable toxicity in clinical trials, particularly given the aggressive nature of high-risk multiple myeloma.
- Manufacturing Scale
- Allogene’s ability to transition from preclinical data to large-scale, consistent manufacturing of off-the-shelf CAR T products will be crucial for realizing its commercial ambitions and addressing patient demand.
- Regulatory Pathway
- The FDA’s acceptance of Allogene’s gene-editing approach for autoimmune disease, specifically the use of CRISPR technology, will set a precedent for similar therapies and influence the broader regulatory landscape.
Related topics